ICP-B02 SC / InnoCare, Keymed Biosciences, Prolium Bioscience - LARVOL DELTA

InnoCare Releases 2024 Interim Results and Business Highlights (Businesswire) - P=NA | N=NA | "ICP-B02 is a CD20xCD3 bispecific antibody co-developed with Keymed. Data from both the intravenous infusion (IV) and the subcutaneous (SC) formulations have shown good efficacy of ICP-B02 in patients with follicular lymphoma (FL) and DLBCL. All 15 patients who were treated with ICP-B02 at doses ≥6mg achieved response, resulting in an ORR of 100%. All patients who achieved CR maintained the remission as of the cutoff date. Based on the encouraging results of ICP-B02 as a single agent, the Company is planning for a dose expansion study of ICP-B02 in combination with other immunochemotherapies targeting earlier lines of treatment in NHL patients."

Clinical data • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

SUBCUTANEOUS CM355, A NOVEL BISPECIFIC CD20/CD3 ANTIBODY SHOWED PROMISING EFFICACY AND FAVORABLE SAFETY PROFILE IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (EHA 2024) - P1/2 | "At the doses evaluated, CM355 SC demonstrated favorable safety profile and promising efficacy in patientswith R/R B-cell NHL. All CRS events were manageable with minimal intervention. Rapid and deep responses, aswell as the convenience of SC formulation, support further clinical development for treatment of B-cell NHL."

Clinical • Anemia • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

InnoCare Releases 2022 Annual Results and Business Highlights (Businesswire) - "ICP-B02 (CM355): The IND application for ICP-B02 subcutaneous (SC) formulation was approved for clinical trial by the CDE in March 2023."

IND • Oncology